Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Long-Term Debt Repayments (2015 - 2023)

Avalo Therapeutics posted quarterly Long-Term Debt Repayments of $6.0 million for Q2 2023, down 60.0% year-on-year from $15.0 million in Q2 2022, and up 140.52% on a QoQ basis from -$14.8 million in Q4 2022.

Avalo Therapeutics (AVTX) has 6 years of Long-Term Debt Repayments data on file, last reported at $6.0 million in Q2 2023.

  • For the quarter ending Q2 2023, Long-Term Debt Repayments fell 60.0% year-over-year to $6.0 million; the trailing twelve-month figure through Dec 2024 stood at $6.0 million (down 3.13% YoY), and the FY2023 full-year result was $21.2 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q2 2023 stood at $6.0 million, up from -$14.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $15.0 million in Q2 2022 and bottomed at -$14.8 million in Q4 2022.
  • The 3-year median for Long-Term Debt Repayments is $24342.0 (2019), against an average of $921448.6.
  • Peak annual rise in Long-Term Debt Repayments reached 60.0% in 2023, while the deepest fall reached 60.0% in 2023.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $183114.0 in 2019, then sank by 8185.67% to -$14.8 million in 2022, then surged by 140.52% to $6.0 million in 2023.
  • The last three Long-Term Debt Repayments figures came in at $6.0 million (Q2 2023), -$14.8 million (Q4 2022), and $15.0 million (Q2 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Avalo Therapeutics 317.29 Mn 317.29 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 6.00 Mn
Jun 30, 2023 6.00 Mn
Dec 31, 2022 -14.81 Mn
Dec 31, 2022 -14.81 Mn
Jun 30, 2022 15.00 Mn
Jun 30, 2022 15.00 Mn
Dec 31, 2019 183,114.00
Dec 31, 2019 183,114.00
Sep 30, 2019 24,342.00
Sep 30, 2019 24,342.00
Jun 30, 2019 24,342.00
Jun 30, 2019 24,342.00
Mar 31, 2019 24,342.00
Mar 31, 2019 24,342.00
Sep 30, 2017 606,610.00
Sep 30, 2017 606,610.00
Jun 30, 2017 892,721.00
Jun 30, 2017 892,721.00
Mar 31, 2017 874,700.00
Mar 31, 2017 874,700.00
Dec 31, 2016 854,732.00
Dec 31, 2016 854,732.00
Sep 30, 2016 836,474.00
Sep 30, 2016 836,474.00
Jun 30, 2016 819,119.00
Jun 30, 2016 819,119.00
Mar 31, 2016 803,900.00
Mar 31, 2016 803,900.00
Dec 31, 2015 787,946.00
Dec 31, 2015 787,946.00
Sep 30, 2015 770,864.00
Sep 30, 2015 770,864.00